The SARS-CoV-2 pandemic precipitated an unprecedented scientific, financial, and regulatory effort that culminated in the global deployment of vaccines based on innovative platforms—messenger RNA and adenoviral vectors—and traditional technologies. The shortening of clinical development timelines through mechanisms such as Operation Warp Speed in the United States and accelerated assessments (rolling reviews) from the European Medicines Agency (EMA) made it possible to decisively mitigate global morbidity and mortality.

However, the mass administration to billions of subjects exposed the inherent limitations of pharmacovigilance in phase III clinical trials, revealing rare but clinically significant safety signals that altered public health strategies. This report summarizes, from an epidemiological and international pharmaceutical law perspective, the regulatory restrictions, validated adverse effects, resulting litigation, and contractual disputes that have marked the evolution of this phenomenon between 2020 and May 2026.

Module 1 — The Silent Withdrawal

AstraZeneca case (Vaxzevria): From European suspension to global withdrawal

The ChAdOx1-S (recombinant) vaccine, marketed as Vaxzevria y Covidhield, It constituted one of the initial pillars of global immunization, demonstrating the efficacy of 100% against severe disease in clinical trials. In mid-March 2021, a critical accumulation of spontaneous reports of atypical thromboembolic events forced drastic regulatory intervention in Europe.

Denmark, Norway, and Germany were pioneers in discontinuing the procedure after identifying unusual patterns of cerebral blood clots combined with abnormally low platelet levels. Danish-Norwegian cohort studies (n=281,264 recipients) reported concerning standardized incidence rates of venous thromboembolism. 1.97 (CI 95%: 1.50–2.54) and thrombocytopenia 3.02 (CI 95%: 1.76–4.83) within 28 days of vaccination.

On March 18, 2021, the EMA and its Pharmacovigilance Risk Assessment Committee (PRAC) formally intervened, recognizing these events as side effects in April 2021. «"very strange"» but biologically plausible. Most European countries implemented strict age restrictions, limiting Vaxzevria to populations over 60 years of age.

The product life cycle culminated on March 27, 2024, When the European Commission, at the request of the marketing authorization holder (AstraZeneca AB), permanently revoked the authorization in the EU. Weeks later, on April 23, 2024, the Therapeutic Goods Administration The Australian TGA cancelled the registration. The corporation justified the withdrawal on the grounds that... «"surplus of newer vaccines"» and a drop in sales from USD 4,000 M (2021) to USD 12 M (2023).

Janssen Case (Johnson & Johnson): Cancellation of Emergency Use in the U.S.

The adenoviral vector vaccine Ad26.COV2.S experienced a similar trajectory. In April 2021, the FDA and CDC issued an immediate clinical pause after confirming six severe cases of cerebral venous sinus thrombosis with thrombocytopenia among more than 6.8 million doses administered.

Although the pause was lifted on April 23, 2021, the VAERS and v-safe systems documented a worsening situation. By March 2022, the analysis revealed a reporting rate of 3.23 cases of TTS and 0.48 deaths per million doses, ...disproportionately affecting women aged 30 to 49. In December 2021, the ACIP issued a preferential recommendation in favor of mRNA vaccines over Janssen.

Finally, citing the expiration of the last federal lots and the company's refusal to update the composition for emerging variants, the FDA definitively revoked EUA 27205 on June 1, 2023, under the signature of Dr. Peter Marks, Director of CBER.

Nordic restrictions on mRNA vaccines

While mRNA platforms demonstrated a superior profile compared to adenoviral vectors in terms of thrombotic events, prospective surveillance identified a disproportionate risk of cardiac inflammation. In early October 2021, the public health agencies of Sweden, Denmark, Finland, and Norway Spikevax (Moderna) was suspended or discouraged in men under 30 years of age., transitioning to Comirnaty (Pfizer) as the exclusive vaccine in that cohort.

Module 2 — Litigation and Transparency

Civil lawsuits in the United Kingdom (London High Court)

AstraZeneca faces consolidated civil claims in the High Court of London under the Consumer Protection Law. Flagship cases include Jamie Scott —diagnosed with vaccine-induced immune thrombocytopenia (VITT) after his immunization in April 2021 and with permanent brain damage— and Anish Tailor, whose wife Alpa Tailor died from VITT-induced blood clots and brain hemorrhage.

Represented by specialized law firms such as Hausfeld y Leigh Day, Dozens of litigants argue that the biological product was legally «"defective"» in its risk-benefit analysis. The corporate defense maintains that patient safety was always the priority.

The systemic failure of state compensation programs

The near-absolute legal immunity clauses granted to manufacturers forced victims to resort to compensation schemes. no-fault. Comprehensive analyses reveal systemic deficiencies:

The HRSA database (May 2026) reveals the magnitude of US administrative denials: 7,066 rejected claims. The reasons are procedural: 2 768 due to lack of medical records, 2 619 for failing to meet the 1-year filing deadline. TTS/VITT cases have generated the largest payouts, notably one claim compensated with USD 5,942,538.84.

The European dispute: "Pfizergate" and case T-36/23 before the CJEU

At the level of supranational administrative law, the most disruptive litigation was the case Stevi and The New York Times v Commission (T-36/23) before the Grand Chamber of the General Court of the CJEU. The dispute arose from the framework agreement for the acquisition of 1.8 billion doses of mRNA vaccines for approximately €15.5 per dose (~€35 billion), negotiated directly via SMS and telephone calls between Ursula von der Leyen and Albert Bourla.

He May 14, 2025, The General Court ruled unequivocally in favor of the NYT, overturning the Commission's decision. The ruling dismantled the «"evasive justifications"» and established axiomatically that informal communications that determine sovereign decisions are subject to legal scrutiny.

Forced release of Pfizer data (USA, Case 4:21cv01058)

The organization Public Health and Medical Professionals for Transparency (PHMPT) sued the FDA under the Freedom of Information Act (FOIA). In its defense, the FDA proposed releasing 500 pages per month—a timeline that would have delayed full disclosure until next year. 2097.

«"Excessive delay fuels conspiracy theories and undermines public trust in government evaluation."»— Judge Mark Pittman, Northern District of Texas, acceleration order to 55,000 pages per month.

Module 3 — Confirmed Syndromes

VITT/TTS: Adenoviral vector-induced immune thrombosis

He Vaccine-Induced Immune Thrombocytopenia Syndrome (VITT/TTS) It is a severe immunological phenotype inextricably linked to non-replicating adenoviral vector platforms (AstraZeneca's ChAdOx1-S and Janssen's Ad26.COV2.S). Pathophysiologically, the syndrome is triggered by the formation of abnormal IgG antibodies against the virus. platelet factor 4 (PF4).

The clinical picture manifests between days 4 and 30 post-vaccination, characterized by arterial or venous thrombosis in unusual locations—predominantly cerebral venous sinus (CVST) thrombosis and splanchnic thrombosis. The early incidence was ~1 case per 150,000 vaccinated. The initial mortality rate was around 50%, later reduced to 5–22% thanks to WHO guidelines that contraindicate heparin and promote intravenous immunoglobulin.

Post-mRNA myocarditis: the risk concentrated in young men

Acute myocardial inflammation was formally included as a warning in the package inserts for Comirnaty (Pfizer) and Spikevax (Moderna) by the FDA and EMA. The statistical signal is highly concentrated in adolescent and young adult males (12–29 years), appearing within the first 7 days after the second dose.

Analysis of the American Heart Association Over 43 million people demonstrate:

Guillain-Barré: a specific Janssen sign

Guillain-Barré syndrome (GBS) was causally associated with Ad26.COV2.S. Vaccine Safety Datalink documented an unadjusted incidence of 32.4 cases/100,000 person-year In the 21 days following Janssen, the incidence was dramatically higher than the baseline incidence of 1–2/100,000. The incidence after mRNA vaccines (1.3/100,000) was not statistically significant.

Heavy menstrual bleeding: a signal initially silenced

Initial alerts were downplayed, but the prospective workload (>34,000 reports to EudraVigilance) necessitated a formal review. October 2022, EMA's PRAC ruled to add the «"heavy menstrual bleeding"» as an adverse effect with «"reasonable possibility of causal association"».

Norwegian studies (Trogstad et al.) established a Relative Risk of RR 1.90 (1st dose) y RR 1.84 (2nd dose). Clinically, the abnormalities are transient (< 8 days of variation) and show no impact on fertility rates.

Module 4 — Ventavia, Indemnity and Sovereign Immunity

The Ventavia case: Brook Jackson's complaint in the BMJ

In November 2021, The BMJ He published a devastating investigation by journalist Paul Thacker based on the revelations of Brook Jackson, regional director of Ventavia Research Group—a CRO subcontracted by Pfizer to operate Phase III trial sites in Texas. Audited internal documents revealed systemic failures: breaches of double-blinding, data falsification, medical staff without certified training, negligent cold storage, and delays in following up on adverse events.

Jackson filed a lawsuit qui tam under the False Claims Act (Civil Action) 1:21-CV-00008-MJTOn March 31, 2023, Judge Michael J. Truncale ruled in favor of the pharmaceutical companies. The court He did not provide evidence to refute the anomalies, but ruled under the standard of «"Materiality"»The government—notified of the failures in September 2020—proceeded with the authorizations and disbursements anyway.

Sovereign indemnity: the price for Latin America

Investigations of The Bureau of Investigative Journalism They revealed that Pfizer imposed exceptional liability exemption demands on Latin American republics. In Brazil and Argentina, deliveries of biologics were conditioned on the states:

• They would grant indefinite civil amnesty for any side effects.
• They were erected as financial guarantors of the laboratory.
• They will lift sovereign immunity on state assets.
• They registered central bank reserves, military bases and offshore deposits as attachable guarantee funds.

According to leaked drafts, Pfizer intended to guarantee indemnity even in scenarios where injuries were caused by malpractice, negligence, malice, or fraud on the part of the company itself. The final Brazilian contract obligated the nation to submit to the jurisdiction of courts in New York, mandating legally secret arbitration.

Monopolistic corporations used control of essential medical technology as a tool to erode constitutional dogmas of public administrative law.— Synthesis of academic analyses of global health and international law.

Forensic Balance: What Six Years Taught Us

The clinical-legal record of the vaccine response to the pandemic leaves four unequivocal lessons for epidemiology and pharmaceutical law in the 21st century:

First, The compressed timelines of clinical development necessarily shift some of the detection of rare signals to the post-marketing stage. VITT/TTS, mRNA myocarditis, and post-Janssen GBS are evidence that active pharmacovigilance worked: agencies detected, validated, and intervened within months.

Second, the aggregate risk-benefit balance remains favorable for most cohorts. The documented exception—the second dose of Spikevax in men < 30 years—justified surgical interventions, not mass withdrawal.

Third, the compensation systems no-fault They have failed systemically in the US and UK (approved at ~0.3% and ~1.1%, respectively), while Japan has demonstrated that an inclusive approach allows for fiscally sustainable rates of 63%. The asymmetry is political, not actuarial.

Room, contractual opacity It is indefensible. in a liberal democracy. The precedent of the CJEU (T-36/23) and the Pittman order in Texas establish cross-cutting jurisprudence: informal communications that compromise sovereign decisions and clinical data that support authorizations are subject to legal scrutiny.

The question is no longer whether the pandemic response was scientifically justifiable—it was. The question is whether the governance mechanisms, contract transparency, and compensation for victims are adequate for the next health emergency. As of May 2026, the documented response suggests that They are not.